| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg | |||
| Other Sizes |
| ln Vitro |
Ophiopojaponin C was evaluated for cytotoxic activity against two human tumor cell lines: MG-63 (osteosarcoma) and SNU387 (hepatoma) using the MTT assay. The compound showed no significant cytotoxicity against either cell line, with IC50 values greater than 40 μM for both MG-63 and SNU387 cells. [1]
|
|---|---|
| Cell Assay |
The cytotoxic activity of Ophiopojaponin C was assessed using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) method. Briefly, MG-63 and SNU387 cells were seeded in 96-well plates at a density of 5 × 10^3 cells per well in culture medium. The cells were cultivated at 37°C for 24 hours in a 5% CO2 atmosphere. Subsequently, the cells were treated with various concentrations of Ophiopojaponin C and incubated for 48 hours. After the incubation, 100 μl of MTT solution (1 mg/ml) was added to each well and the plate was incubated for an additional 4 hours. Then, 100 μl of a "triplex solution" (10% SDS / 5% iBuOH / 12 mM HCl) was added to each well, and the plate was allowed to stand overnight in the incubator. The absorbance was recorded on a microplate reader at 490 nm. Cell viability (%) was measured, and the cell growth curve was plotted. The IC50 values were calculated by the Reed and Muench method. Under these experimental conditions, Ophiopojaponin C exhibited IC50 > 40 μM against both MG-63 and SNU387 cell lines. [1]
|
| References | |
| Additional Infomation |
Ophiopojaponin C is one of five previously undescribed steroidal saponins isolated from the tubers of Ophiopogon japonicus (Thunb.) Ker-Gawl. (family Liliaceae). Its aglycone structure features a rare 12α,14α-dihydroxy substitution on a homo-aro-cholestane skeleton. The compound was isolated from the n-BuOH extract of the plant material using a combination of macroporous resin, silica gel, RP-C18 column chromatography, and preparative HPLC. The cytotoxicity screening revealed that it was inactive against the tested cancer cell lines at the highest concentration tested (40 μM). In contrast, several known spirostane-type glycosides (compounds 11, 13, 15-17) showed potent cytotoxic activity with IC50 values ranging from 0.76 to 27.0 μM against MG-63 and SNU387 cells. [1]
|
| Molecular Formula |
C46H72O17
|
|---|---|
| Molecular Weight |
897.0537
|
| Exact Mass |
886.456
|
| CAS # |
911819-08-4
|
| PubChem CID |
90477999
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.5±0.1 g/cm3
|
| Melting Point |
215-217°C
|
| Index of Refraction |
1.638
|
| LogP |
4.77
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
17
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
63
|
| Complexity |
1700
|
| Defined Atom Stereocenter Count |
26
|
| SMILES |
O[C@]12[C@H](C)[C@]3(OC[C@H](C)CC3)O[C@H]1C[C@]1([C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]21C)O[C@@H]1O[C@H](CO)[C@@H](O[C@@H]2OC[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O)O
|
| InChi Key |
MQTJXIHSKXORQL-RFMZWHELSA-N
|
| InChi Code |
InChI=1S/C46H72O17/c1-19-10-13-46(56-17-19)20(2)32-30(63-46)16-28-26-9-8-24-14-25(59-23(5)47)15-31(45(24,7)27(26)11-12-44(28,32)6)60-43-40(62-42-38(54)36(52)33(49)21(3)57-42)39(34(50)22(4)58-43)61-41-37(53)35(51)29(48)18-55-41/h8,19-22,25-43,48-54H,9-18H2,1-7H3/t19-,20+,21+,22-,25-,26-,27+,28+,29-,30+,31-,32+,33+,34+,35+,36-,37-,38-,39+,40-,41+,42+,43-,44+,45+,46-/m1/s1
|
| Chemical Name |
[(1S,2S,4S,5'R,6R,7S,8R,9S,12S,13R,14R,16R)-14-[(2S,3R,4S,5S,6R)-5-hydroxy-6-methyl-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy-4-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxyoxan-2-yl]oxy-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icos-18-ene-6,2'-oxane]-16-yl] acetate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.1148 mL | 5.5738 mL | 11.1477 mL | |
| 5 mM | 0.2230 mL | 1.1148 mL | 2.2295 mL | |
| 10 mM | 0.1115 mL | 0.5574 mL | 1.1148 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
